A Phase I, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of balcinrenone in patients with mild and moderate hepatic impairment in comparison to a matched healthy control group.

开始日期2024-05-02

申办/合作机构

AstraZeneca PLC

NCT04595370 / Completed临床2期

A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease

The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF [below 60%]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR [between ≥ 20 and ≤ 60 mL/min/1.73 m^2, with at least 20% of participants with eGFR ≥ 20 to <30 mL/min/1.73^2 and a maximum of 35% of participants with eGFR ≥ 45 mL/min/1.73 m^2]).

开始日期2021-01-26

申办/合作机构

AstraZeneca PLC

NCT04686591 / Completed临床1期

A Phase I, Open-label Study of Absolute Bioavailability and Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]AZD9977 in Healthy Male Subjects

Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration

开始日期2020-12-21

申办/合作机构

AstraZeneca PLC

[+1]

100 项与 Balcinrenone 相关的临床结果

登录后查看更多信息

100 项与 Balcinrenone 相关的转化医学

登录后查看更多信息

100 项与 Balcinrenone 相关的专利（医药）

登录后查看更多信息

项与 Balcinrenone 相关的文献（医药）

2023-12-01·Current cardiology reports

Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes

Review

作者: Kintscher, Ulrich

PURPOSE OF REVIEW:

Novel non-steroidal mineralocorticoid receptor (MR) antagonists (MRAs) are a new class of drugs blocking adverse MR-mediated effects with an improved benefit-risk profile compared to steroidal MRAs. This review will provide information on the preclinical and clinical pharmacology of this new drug class and will discuss their future clinical applications in patients with cardiorenal disease.

RECENT FINDINGS:

Non-steroidal MRAs such as esaxerenone, AZD9977, apararenone, ocedurenone (KBP-5074), and finerenone are newly approved or in clinical development for patients with cardiorenal disease including type 2 diabetes (T2D) and chronic kidney disease (CKD), hypertension -/+ CKD or heart failure. Unlike steroidal MRAs, non-steroidal MRAs do not induce sex hormone-related side effects and appear to mediate a lower risk of hyperkalemia while maintaining compelling clinical efficacy. Recently, new data from several clinical trials with non-steroidal MRAs have been published (e.g., FIDELIO-DKD, FIGARO-DKD, ESAX-DN, and BLOCK-CKD), and additional studies are currently underway (e.g., FINEARTS-HF and CLARION-CKD). These data and the clinical scientific basis for the ongoing studies will be discussed. Non-steroidal MRAs have been extensively explored in diabetic kidney disease. Selected candidates of this drug class reduced UACR in patients with varying degrees of CKD and T2D and have shown convincing cardiorenal protection, in particular finerenone. Furthermore, finerenone is currently tested in patients with heart failure with preserved ejection fraction.

2023-11-01·Steroids

Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators

Article

作者: Koca, Duygu ; Lother, Achim

Mineralocorticoid receptor (MR) antagonists have shown remarkable benefits in the treatment of cardiovascular disease. However, their underutilization in clinical practice may be attributed to concerns regarding the risk of hyperkalemia. An ideal selective MR modulator would inhibit the detrimental effects of MR in non-epithelial cells of the cardiovascular system while sparing its physiological function in kidney epithelial cells, thereby reducing the risk of adverse events. To address this issue, a new generation of non-steroidal MR antagonists, including esaxereneone, balcinrenone, ocedurenone, and finerenone, has been developed with distinct molecular structures and pharmacology. They share a mechanism of action that is different from the previously developed steroidal MR antagonists, leading to altered co-regulator interaction, potentially involving conformational changes of the receptor. Interfering with MR co-regulator interaction or the co-regulator itself may enable selective targeting of downstream signaling cascades and - in the long term - lead to more personalized medicine. In this review article, we summarize what is currently known about the mechanisms of action of the different MR antagonists with a focus on MR co-factor interaction and what may be inferred from this for future developments.

Journal of clinical medicine

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease

Review

作者: Shah, Monarch ; Awad, Alaa S ; Abdel-Rahman, Emaad M

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) present a promising therapeutic option in cardiorenal diseases, mitigating the limitations of steroidal MRAs. Finerenone, a third-generation nonsteroidal MRA, has demonstrated beneficial effects in heart failure (HF) and chronic kidney disease (CKD). Clinical trials, including FIDELIO-DKD and FIGARO-DKD, revealed finerenone’s efficacy in improving kidney and cardiovascular (CV) outcomes. Patients with CKD and type 2 diabetes (T2DM) on finerenone experienced reduced rates of cardiovascular events, including hospitalization for HF. However, these trials excluded symptomatic HF patients, focusing on asymptomatic or early-stage HF. The ongoing FINEARTS-HF trial evaluates finerenone in HF with preserved ejection fraction (HFpEF). Additionally, studies exploring finerenone and sodium-glucose cotransporter 2 (SGLT2) inhibitors’ (Empagliflozin) combination effects in CKD and T2DM (CONFIDENCE) and the selective MR modulator AZD9977 with another SGLT2 inhibitor (dapagliflozin) in HF and CKD (MIRACLE) aim to expand treatment options. While SGLT-2 inhibitors were shown to reduce hyperkalemia risk in FIDELIO-DKD and potentially lower new-onset HF incidence in FIGARO-DKD, further research is essential. So far, the evidence for the beneficial effect of finerenone in the spectrum of cardiorenal diseases is based only on the results of studies conducted in patients with T2DM, and clinical trials of finerenone in patients with nondiabetic kidney disease are ongoing. Nonsteroidal MRAs hold significant potential as pivotal treatment targets across the cardiorenal disease spectrum. This review will focus on the effects of finerenone on cardiorenal disease.

项与 Balcinrenone 相关的新闻（医药）

2024-06-26

·FiercePharma

New CKD drugs are promising, but need stronger efficacy data, kidney docs say: GlobalData

In total, the chronic kidney disease market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Though a host of drugs currently under development are poised to massively expand the existing market for chronic kidney disease (CKD) treatments, they’ll need to go further to win the support of doctors, according to a new report. The segment is expected to expand at a compound annual growth rate of nearly 20% over the course of a decade, according to GlobalData’s estimates. The report comprises the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan, though GlobalData noted that the U.S. will be a disproportionately large contributor to that growth, thanks to its higher prevalence of CKD and costs of prescription medications. In total, the CKD market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Among those now in development are ProKidney’s cell therapy rilparencel, also known as React, and AstraZeneca’s combinations of zibotentan and dapagliflozin, and balcinrenone and dapagliflozin—all of which are currently in clinical trials. Meanwhile, Novo Nordisk is also exploring a potential expanded indication for Ozempic in CKD. Just last month, Novo shared results from its FLOW study of once-weekly Ozempic’s ability to reduce the risk of major kidney disease events in patients with both CKD and Type 2 diabetes. With a median follow-up period of nearly three and a half years, the study found that participants treated with the GLP-1 had an average 24% risk reduction compared to those assigned to the placebo group, and their rate of kidney function decline was “significantly slower.” Additionally, semaglutide was shown to reduce the risk of major cardiovascular events by 18% and all-cause mortality by 20%. Following that data drop, Novo confirmed that it will pursue expanded approvals for Ozempic in the U.S. and Europe by the end of this year. Despite the promising results from the studies of those and other potential new CKD therapeutics so far, according to GlobalData, many kidney doctors have yet to be convinced to shake up their existing CKD treatment standards and have “mixed views” about tacking on another drug to their patients’ current regimens. “It will be easier for new drug entrants to capture CKD market share if they offer a novel mechanism of action or help to improve compliance,” Kajal Jaddoo, senior pharma analyst at GlobalData, said in the report. “Overall, nephrologists surveyed by GlobalData have indicated that the pipeline for CKD is somewhat promising, but a significant improvement in efficacy would have to be demonstrated by any therapy for it to become either a replacement or add-on to the existing therapies.”

临床结果上市批准细胞疗法

2024-06-09

·医药观澜

10多款1类新药在中国获批临床，来自阿斯利康、信达生物、华东医药等公司

▎药明康德内容团队编辑根据中国国家药监局药品审评中心（CDE）官网数据，近两周有10多款1类新药首次获得临床试验默示许可。通过梳理，这些新药涵盖小分子新药、抗体偶联药物（ADC）、单抗、siRNA疗法等，它们拟用于治疗癌症、慢性肾病患者、化疗相关性腹泻、亨廷顿舞蹈病、痛风等。本文将对其中部分产品进行简要介绍，仅供读者参阅。图片来源：123RF 阿斯利康：balcinrenone/达格列净胶囊作用机制：盐皮质激素受体调节剂（MRM）+SGLT2抑制剂适应症：慢性肾病患者心力衰竭阿斯利康申报的balcinrenone达格列净胶囊获批临床，拟用于降低心力衰竭合并肾功能损害患者发生心力衰竭事件和心血管死亡的风险。根据阿斯利康官网资料，这是其正在开发的慢性肾病组合疗法中的一款，为盐皮质激素受体调节剂（MRM）+SGLT2抑制剂，目前在国际范围内处于3期临床研究阶段。达格列净为一款SGLT2抑制剂，已经获得美国FDA批准治疗慢性肾病（CKD）患者，阿斯利康正在临床试验中检验多种创新疗法与达格列净联用的效果，以求进一步改善CKD患者的治疗，其中balcinrenone与达格列净联用可能增强对CKD患者心力衰竭的治疗。艾伯维：budigalimab 作用机制：抗PD-1单抗适应症：肝细胞癌艾伯维申报的budigalimab获批临床，拟联合livmoniplimab治疗在一线免疫检查点抑制剂治疗后出现疾病进展的局部晚期或转移性Child-Pugh A级肝细胞癌（HCC）。根据艾伯维公开资料，ABBV-151（livmoniplimab）是其与argenx合作开发的GARP- TGF-β1人源化单克隆抗体抑制剂，正在开发用于治疗癌症；ABBV-181（budigalimab）是一种抗PD-1人源化单克隆抗体，正在开发用于与艾伯维其他分子联合治疗实体瘤和血液系统恶性肿瘤。在国际范围内，该联合疗法治疗肝癌和非小细胞肺癌处于2期临床研究阶段。汉康生技：HCB101注射液作用机制：SIRPα融合蛋白适应症：实体瘤和非霍奇金淋巴瘤根据汉康生技（HanchorBio）新闻稿，HCB101注射液是该公司管线中的第一个项目，为一个与IgG4-Fc连结、经过工程优化的SIRPα融合蛋白。它通过阻断巨噬细胞和癌细胞之间的“别吃我”信号来触发巨噬细胞的吞噬活性。研究表明，HCB101在癌细胞内及肿瘤微环境引发了明显不同的基因表现型态，表示其可能具有独特的作用机制。此前，该产品已经在美国和中国台湾地区获批临床，并自2023年4月开始开展全球多中心多地区临床试验。本次在中国获批临床，拟用于治疗晚期实体瘤及复发难治性非霍奇金淋巴瘤。派金生物：注射用重组酰化胰高血糖素样肽2类似物作用机制：GLP-2类似物适应症：化疗相关性腹泻根据派金生物新闻稿，本次获批临床的是一款重组酰化胰高血糖素样肽2（GLP-2）类似物，为一款长效重组多肽。研究表明，GLP-2类似物可以增加绒毛高度及隐窝深度，加强肠道上皮屏障，从而减轻局部炎症并改善肠道通透性，促进肠适应。派金生物新闻稿介绍，除了用于预防和治疗化疗严重腹泻外，在非临床试验中，该产品还被证明有开发成一周一次给药治疗短肠综合征、慢性肠炎等的临床价值。艾码生物：ER2001注射液作用机制：siRNA疗法适应症：早期显性亨廷顿舞蹈病根据艾码生物新闻稿介绍，ER2001注射液通过利用人体或动物体的自身器官组织作为生物反应器，在体内被“加工”成为活性形式的siRNA，并组装进入“生物反应器”同步产生的中枢神经系统靶向的内源外泌体中，经外泌体分泌“运输”到神经元细胞，可降解其中突变亨廷顿蛋白（mHTT）的mRNA，从而产生药效。该产品获批临床的适应症为早期显性亨廷顿舞蹈病（HD）。HD是一种遗传性神经系统变性病，临床表现为运动障碍、精神症状、认知障碍等。随着病程发展，疾病晚期表现为僵直、少动为主的帕金森症状，往往严重影响患者的生活质量和寿命。中美华东：注射用HDM2005 作用机制：靶向ROR1的ADC 适应症：晚期恶性肿瘤根据中美华东新闻稿介绍，注射用HDM2005是一款靶向ROR1的ADC，现有数据显示其具有良好的成药性和安全性。ROR1是一种典型的肿瘤胚胎蛋白，该靶点具有广谱抗肿瘤性，在多类肿瘤中高度表达，是潜力ADC靶点。HDM2005已经在临床前的药效学研究、药代动力学研究及安全性评价中展现出良好的抗肿瘤活性和安全性。该产品本次获批临床的适应症为晚期恶性肿瘤。加科思：JAB-30355片作用机制：p53 Y220C激活剂适应症：携带TP53 Y220C突变的晚期实体瘤 p53 Y220C突变是一种发生在p53的DNA结合域的常见突变，携带这一突变的p53难以维持稳定的DNA结合域构象，无法完成应有的DNA调控功能。JAB-30355正是加科思自主研发的一种口服生物活性小分子激活剂，拟开发用于治疗携带P53 Y220C突变的局部晚期或转移性实体瘤患者。信达生物：替古索司他片作用机制：XOI靶向小分子适应症：痛风信达生物申报的1类新药替古索司他片已经获得临床试验默示许可，拟开发治疗痛风。根据信达生物公开资料，替古索司他片（IBI128）是一款全新非嘌呤类似物——黄嘌呤氧化酶抑制剂（XOI）。信达生物于2022年12月与总部位于韩国的LG公司化学达成一项约9550万美元的合作，从而获得该产品在中国的开发和商业化权利。除了上述产品，近期还有其他1类新药获批临床，或获批针对新适应症开展临床研究，限于篇幅，此处不再一一赘述。希望这些1类新药后续临床研究进展顺利，早日取得突破，造福患者。参考资料： [1]中国国家药监局药品审评中心（CDE）官网.Retrieved June 8，2024, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [2]各公司官网及公开资料本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床2期临床3期抗体药物偶联物siRNA

2023-05-05

·PRNewswire

Chronic Kidney Disease Competitive Landscape Report 2023: Comprehensive Insights About 75+ Companies and 95+ Drugs

DUBLIN, May 5, 2023 /PRNewswire/ -- The "Chronic Kidney Disease - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 95+ drugs in Chronic Kidney Disease Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in a Phase 2 clinical program for ADPKD. In February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca's cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio. In January 2023, The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced. In November 2022, The Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, which designed, conducted and analyzed EMPA-KIDNEY in a scientific collaboration with Boehringer Ingelheim and Eli Lilly and Company, announced that EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo (HR; 0.72; 95% CI 0.64 to 0.82; P< 0.0001). In October 2022, Revelation Biosciences Inc. announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner in the medium and high dose groups (21.7% reduction (p < 0.05) and 29.3% (p < 0.05), respectively) and was comparable to a known TGF inhibitor of fibrosis used as a positive control (38.1% reduction (P < 0.05)). In October 2022, French Biopharma Company, Poxel SA announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator - and is also a phase 2 ready ADPKD asset, subject to additional financing. In-depth Commercial Assessment: Chronic Kidney Disease Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Current Treatment Scenario and Emerging Therapies: How many companies are developing Chronic Kidney Disease drugs? How many Chronic Kidney Disease drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Chronic Kidney Disease and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players Boehringer Ingelheim Eli Lilly and Company Reata Pharmaceuticals Novo Nordisk KBP Biosciences AstraZeneca Allena Pharmaceuticals SCOHIA PHARMA DiaMedica Therapeutics CinCor Pharma Galapagos NV Sentien Biotechnologies, Inc. Regeneron Pharmaceuticals UnicoCell Biomed OccuRx Pharmicell Lisata Therapeutics Unicycive Therapeutics Senda Biosciences Sarfez Pharmaceuticals Rege Nephro Orgenesis GNI Group Algomedix Maze Therapeutics Chinook Therapeutics Angion Biomedica Corp Arch Biopartners Scohia Pharma Algernon Pharmaceuticals TICEBA GmbH Key Products Empagliflozin Bardoxolone methyl Ziltivekimab KBP-5074 AZD9977 ALLN-346 BI-685509 SCO-792 DM199 Baxdrostat GLPG2737 SBI-101 REGN5459 ELIXCYTE FT011 Cellgram-CKD CLBS201 UNI-494 Research Program SZ007 Renal progenitor cells MSCKD F351 Research programme: TRPC6 antagonist APOL1 Programme Research and discovery programs: severe chronic kidney disease ROCK2 Inhibitor LSALT peptide SCO-116 Repirinast Polycystic kidney disease (PKD) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

临床结果并购临床2期临床3期孤儿药

100 项与 Balcinrenone 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15418

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	美国	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	日本	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	比利时	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	保加利亚	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	加拿大	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	捷克	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	丹麦	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	德国	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	匈牙利	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	印度	AstraZeneca PLC	2021-01-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03682497 (Pubmed) 人工标引	临床1期	心脏衰竭 \| 肾功能不全	68	AZD9977	網製淵範積鏇襯廠夢衊(夢積齋獵觸廠製鹹顧壓) = 獵繭壓醖積廠遞餘壓鏇膚鬱壓獵鬱鏇繭簾願膚 (襯遞簾衊壓鑰鬱蓋廠願, -5.3 ~ 4.4)	积极	2022-08-15
				spironolactone	網製淵範積鏇襯廠夢衊(夢積齋獵觸廠製鹹顧壓) = 窪艱遞鏇選餘觸夢鹹廠膚鬱壓獵鬱鏇繭簾願膚 (襯遞簾衊壓鑰鬱蓋廠願, -0.8 ~ 7.5)
NCT03435276 (Pubmed) 人工标引	临床1期	高钾血症	27	AZD9977	顧鏇醖獵積廠願糧蓋簾(簾窪鏇積構襯糧窪願淵) = 餘膚廠願糧夢製衊製築鏇鏇鏇蓋衊齋鬱膚遞膚 (遞獵遞網淵壓積蓋鹹憲 )	积极	2020-03-01
				Placebo	顧鏇醖獵積廠願糧蓋簾(簾窪鏇積構襯糧窪願淵) = 鏇鬱齋鹹廠衊廠鹹遞繭鏇鏇鏇蓋衊齋鬱膚遞膚 (遞獵遞網淵壓積蓋鹹憲 )
NCT03682497 (ESC2019)	临床1期	-	27	AZD9977	遞齋齋鹹餘膚繭窪襯齋(範選構選獵醖遞齋廠壓) = A total of 7 adverse events occurred in 4 participants (22.2%) receiving AZD9977 and 8 events occurred in 6 participants (66.7%) receiving placebo, none severe or resulting in withdrawal from the study 襯網積鏇膚艱鹽衊膚夢 (鑰醖積壓繭蓋襯餘醖廠 )	-	2019-09-03
				Placebo